BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...Nancy Stagliano, a biotech veteran who led True North Therapeutics Inc....
BioCentury | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

...Bioverativ Inc. in 2018, which in turn got the product through its own takeout of True North Therapeutics Inc....
...Targets: C1s - Complement component 1 s subcomponent; C5 - Complement 5 Sandi Wong, Staff Writer Bioverativ Inc. True North Therapeutics Inc. Sanofi Complement...
BioCentury | Jan 26, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North Therapeutics Inc....
...NASDAQ:BIVV), Waltham, Mass. Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics plc Bioverativ Inc. Sanofi Swedish Orphan Biovitrum AB True North Therapeutics Inc. Complement...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North Therapeutics Inc....
...Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics plc Biogen Inc. Bioverativ Inc. Sanofi True North Therapeutics Inc. Anti-thrombin...
BioCentury | May 26, 2017
Company News

Bioverativ aquiring True North

...Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The...
...True North Therapeutics Inc. , South San Francisco, Calif. Bioverativ Inc. (NASDAQ:BIVV), Cambridge, Mass. Business: Hematology Shannon Lehnbeuter TNT009 Bioverativ Inc. True North Therapeutics Inc. Complement...
BioCentury | May 26, 2017
Finance

Fast cash

...HBM Healthcare Investments will see a quick return on its investment in True North Therapeutics Inc. less than a...
...and EMA Orphan Drug designation for autoimmune hemolytic anemia. Amran Gowani, Senior Editor, Research & Analytics TNT009 Bioverativ Inc. True North Therapeutics Inc. HBM...
BioCentury | May 23, 2017
Company News

Bioverativ acquiring True North

...Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The...
...the deal to close in mid-2017. Bioverativ slipped $2.19 to $52.50 on Tuesday. Becky Simon TNT009 Biogen Inc. Bioverativ Inc. True North Therapeutics Inc. Complement...
BioCentury | Jan 14, 2017
Company News

Management tracks

...CSO. He was EVP of global biopharmaceuticals at Kadmon Holdings Inc. (NYSE:KDMN). Complement-mediated disease company True North Therapeutics Inc....
BioCentury | Oct 31, 2016
Finance

Complement cash

...mAbs against C1S for undisclosed indications driven by classical complement pathway dysregulation. - Virginia Li Virginia Li True North Therapeutics Inc. Complement...
BioCentury | Oct 24, 2016
Financial News

True North Therapeutics completes venture financing

True North Therapeutics Inc. , South San Francisco, Calif. Business: Hematology, Transplant Date completed: 2016-10-18 Type: Venture financing Raised: $45 million Investors: HBM Healthcare Investments; Redmile Group; Perceptive Advisors; Franklin Templeton; existing investors...
Items per page:
1 - 10 of 34
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...Nancy Stagliano, a biotech veteran who led True North Therapeutics Inc....
BioCentury | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

...Bioverativ Inc. in 2018, which in turn got the product through its own takeout of True North Therapeutics Inc....
...Targets: C1s - Complement component 1 s subcomponent; C5 - Complement 5 Sandi Wong, Staff Writer Bioverativ Inc. True North Therapeutics Inc. Sanofi Complement...
BioCentury | Jan 26, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North Therapeutics Inc....
...NASDAQ:BIVV), Waltham, Mass. Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics plc Bioverativ Inc. Sanofi Swedish Orphan Biovitrum AB True North Therapeutics Inc. Complement...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North Therapeutics Inc....
...Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics plc Biogen Inc. Bioverativ Inc. Sanofi True North Therapeutics Inc. Anti-thrombin...
BioCentury | May 26, 2017
Company News

Bioverativ aquiring True North

...Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The...
...True North Therapeutics Inc. , South San Francisco, Calif. Bioverativ Inc. (NASDAQ:BIVV), Cambridge, Mass. Business: Hematology Shannon Lehnbeuter TNT009 Bioverativ Inc. True North Therapeutics Inc. Complement...
BioCentury | May 26, 2017
Finance

Fast cash

...HBM Healthcare Investments will see a quick return on its investment in True North Therapeutics Inc. less than a...
...and EMA Orphan Drug designation for autoimmune hemolytic anemia. Amran Gowani, Senior Editor, Research & Analytics TNT009 Bioverativ Inc. True North Therapeutics Inc. HBM...
BioCentury | May 23, 2017
Company News

Bioverativ acquiring True North

...Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The...
...the deal to close in mid-2017. Bioverativ slipped $2.19 to $52.50 on Tuesday. Becky Simon TNT009 Biogen Inc. Bioverativ Inc. True North Therapeutics Inc. Complement...
BioCentury | Jan 14, 2017
Company News

Management tracks

...CSO. He was EVP of global biopharmaceuticals at Kadmon Holdings Inc. (NYSE:KDMN). Complement-mediated disease company True North Therapeutics Inc....
BioCentury | Oct 31, 2016
Finance

Complement cash

...mAbs against C1S for undisclosed indications driven by classical complement pathway dysregulation. - Virginia Li Virginia Li True North Therapeutics Inc. Complement...
BioCentury | Oct 24, 2016
Financial News

True North Therapeutics completes venture financing

True North Therapeutics Inc. , South San Francisco, Calif. Business: Hematology, Transplant Date completed: 2016-10-18 Type: Venture financing Raised: $45 million Investors: HBM Healthcare Investments; Redmile Group; Perceptive Advisors; Franklin Templeton; existing investors...
Items per page:
1 - 10 of 34